Editorial: Complete genome sequencing and network modeling to overcome trastuzumab resistance

Pharmacogenomics

Volumn 11, Issue 8, 2010, Pages 1039-1043

  Roukos, Dimitrios H ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

breast; cancer genome; gastric cancer; molecular networks; trastuzumab resistance

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; TRASTUZUMAB; VASCULOTROPIN; HER2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

APOPTOSIS; BREAST CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM METASTASIS; CONGESTIVE HEART FAILURE; DISEASE FREE SURVIVAL; DNA SEQUENCE; DNA TRANSCRIPTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EDITORIAL; GENE AMPLIFICATION; GENE SEQUENCE; GENOTYPE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; METASTASIS POTENTIAL; OVERALL SURVIVAL; PHENOTYPE; POINT MUTATION; PROGNOSIS; PROTEIN EXPRESSION; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMACH CANCER; BIOLOGICAL MODEL; BREAST TUMOR; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENE REGULATORY NETWORK; GENETICS; HUMAN GENOME; METHODOLOGY; MOLECULAR GENETICS; MUTATION; PATHOLOGY; PHARMACOGENETICS; STOMACH TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE REGULATORY NETWORKS; GENOME, HUMAN; HUMANS; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; MUTATION; PHARMACOGENETICS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 77955591497     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.104     Document Type: Editorial

References (32)

1. The human genome at ten. Nature 464(7289), 649-650 (2010).
2. Collins F: Has the revolution arrived? Nature 464(7289), 674-675 (2010).
3. Venter JC: Multiple personal genomes await. Nature 464(7289), 676-677 (2010).
4. Genome sequencing perspectives to improve health by pioneering new methods in public human genome sequencing. Check Hayden E: Human genome at ten: life is complicated. Nature 464(7289), 664-667 (2010).
5. Ledford H: Big science: the cancer genome challenge. Nature 464(7291), 972-974 (2010).
6. Ding L, Ellis MJ, Li S et al.: Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464(7291), 999-1005 (2010).
7. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across fve continents: defning priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24(14), 2137-2150 (2006).
8. Jemal A, Siegel R, Ward E et al.: Cancer statistics 2009. CA Cancer J. Clin. 59, 225-249 (2009).
9. Baselga J, Swain SM: Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9(7), 463-475 (2009).
10. Slamon DJ, Leyland-Jones B, Shak S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
11. van Cutsem E, Kang Y, Chung H et al.: Effcacy results from the ToGA trial: a Phase III study of trastuzumab added to standard chemotherapy (CT) in frst-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J. Clin. Oncol. 27(Suppl.), 18S (2009)
12. Roukos DH: Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann. Surg. Oncol. 17, 14-17 (2010).
13. Petrelli NJ, Winer EP, Brahmer J et al.: Clinical cancer advances 2009: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology J. Clin. Oncol. 27(35), 6052-6069 (2009).
14. Hortobagyi GN: Trastuzumab in the treatment of breast cancer. N. Engl. J. Med. 353(16), 1734-1736 (2005).
15. Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S: Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 13(6), 620-630 (2008).
16. Roukos DH: Personalized cancer diagnostics and therapeutics. Expert Rev. Mol. Diagn. 9(3), 227-229 (2009).
17. Stephens PJ, McBride DJ, Lin ML et al.: Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462(7276), 1005-1010 (2009).
18. Beroukhim R, Mermel CH, Porter D et al.: The landscape of somatic copy-number alteration across human cancers. Nature 463(7283), 899-905 (2010).
19. Landmark study on the crucial role copy number changes across human cancers. International Cancer Genome Consortium: International network of cancer genome projects. Nature 464, 993-998 (2010).
20. Ziogas D, Roukos DH: Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann. Surg. Oncol. 16(7), 1771-1782 (2009).
21. Roukos DH: Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann. Surg. Oncol. 16(4), 795-798 (2009).
22. Rockman MV: Reverse engineering the genotype-phenotype map with natural genetic variation. Nature 456, 738-744 (2008).
23. Bohman T: Mathematics. Emergence of connectivity in networks. Science 323(5920), 1438-1439 (2009).
24. Roukos DH: Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev. Mol. Diagn. 10(1), 33-48 (2010).
25. Novel model with emphasis on clinical data in approaching genotype-phenotype map towards personalized cancer medicine. Schadt EE: Molecular networks as sensors and drivers of common human diseases. Nature 461(7261), 218-223 (2009).
26. Roukos DH: Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3), 283-287 (2010).
27. Roukos DH: Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev. Mol. Diagn. 10(3), 247-250 (2010).
28. Weinberg R: Point: hypotheses frst. Nature 464(7289), 678 (2010).
29. Roukos DH, Katsios C, Liakakos T: Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev. Mol. Diagn. 10(5), 541-545 (2010).
30. Hahn WC, Weinberg RA: Modelling the molecular circuitry of cancer. Nat. Rev. Cancer 2(5), 331-341 (2002).
31. Jones S, Zhang X, Parsons DW: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897), 1801-1806 (2008).
32. Roukos DH: Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J. Clin. Oncol. 28(17), E279-E280 (2010).